```html

Nasopharyngeal Cancer

What is Nasopharyngeal Cancer?

Nasopharyngeal cancer (NPC) is a malignant tumor that originates in the nasopharynx – the upper part of the throat behind the nose and beneath the base of the skull. Unlike most head‑and‑neck cancers, NPC arises from the lining (epithelium) of the nasopharynx and often spreads to nearby lymph nodes early in its course. It is relatively rare in North America and Europe (< 1 case per 100,000 people) but more common in Southeast Asia, North Africa, and the Arctic, suggesting a strong interplay of genetic, viral, and environmental factors.

According to the World Health Organization (WHO), NPC is classified into three histologic types: keratinizing squamous cell carcinoma, non‑keratinizing carcinoma (further divided into differentiated and undifferentiated), and basaloid squamous cell carcinoma. The undifferentiated non‑keratinizing type is the most strongly associated with Epstein‑Barr virus (EBV) infection.

Common Causes

While the exact cause is multifactorial, the following conditions and risk factors have been consistently linked to NPC:

• Epstein‑Barr virus (EBV) infection: Persistent EBV DNA in the nasopharynx is the strongest known risk factor.
• Genetic susceptibility: Certain HLA class I genes (e.g., HLA‑A*02, HLA‑B*58) increase risk, especially in endemic regions.
• Family history: First‑degree relatives with NPC raise an individual’s risk 3–5‑fold.
• Dietary factors: Frequent consumption of salted fish, salted meat, or other nitrosamine‑rich foods.
• Occupational exposure: Dust from woodworking, formaldehyde, and certain industrial chemicals.
• Smoking and alcohol: Although less strongly linked than with other head‑and‑neck cancers, they still contribute to overall risk.
• Chronic inflammation: Long‑standing nasal or sinus infections may create a microenvironment that promotes malignant transformation.
• Immune suppression: HIV infection or use of immunosuppressive drugs (e.g., after organ transplant) can increase susceptibility.
• Radiation exposure: Prior therapeutic radiation to the head and neck region.
• Vitamin D deficiency: Emerging data suggest low serum vitamin D may be associated with higher NPC incidence.

Associated Symptoms

Because the nasopharynx is hidden deep behind the nose, early disease often produces vague or no symptoms. When symptoms appear, they may include:

• Persistent nasal congestion or blockage, often unilateral.
• Recurrent or chronic nosebleeds (epistaxis).
• Serous (watery) or bloody discharge from one nostril.
• Unexplained hearing loss, ear fullness, or frequent “blocked ear” sensation – caused by eustachian tube obstruction.
• Facial pain or a persistent dull headache, especially around the temples.
• Neck mass – often the first sign, due to enlarged cervical lymph nodes.
• Difficulty swallowing (dysphagia) or a feeling that food is “stuck” in the throat.
• Hoarseness, chronic sore throat, or unexplained cough.
• Weight loss, fatigue, or night sweats when disease is advanced.

These signs can mimic common sinus infections or allergies, which is why prompt evaluation is essential if they persist for more than 4–6 weeks.

When to See a Doctor

Seek medical attention promptly if you experience any of the following warning signs, especially when they are new, progressive, or do not improve with standard treatment for sinus or ear problems:

• Unexplained, persistent nasal blockage or discharge lasting > 4 weeks.
• Sudden, painless swelling of a neck lymph node that does not shrink after a few weeks.
• Unilateral (one‑sided) ear fullness, hearing loss, or tinnitus that is not related to an infection.
• Recurring nosebleeds without a clear cause.
• Facial pain or headache that is not relieved by usual pain relievers.
• Unintentional weight loss, night sweats, or persistent fatigue.
• Any combination of the above symptoms that worsens despite treatment.

Early referral to an otolaryngologist (ENT specialist) or a head‑and‑neck oncologist can dramatically improve prognosis.

Diagnosis

Initial clinical evaluation

The work‑up begins with a thorough history and physical exam, focusing on the nasal cavity, nasopharynx, and cervical lymph nodes. The clinician may use a nasal endoscope (a thin, flexible camera) to directly visualize the nasopharyngeal wall.

Imaging studies

• Magnetic Resonance Imaging (MRI): Offers excellent soft‑tissue detail and is the preferred method for assessing local tumor extent.
• Computed Tomography (CT) scan: Helpful for evaluating bone involvement and detecting distant metastases.
• Positron Emission Tomography (PET)/CT: Provides metabolic information, useful for staging and detecting occult spread.

Biopsy & pathology

A tissue sample is required for definitive diagnosis. Endoscopic-guided biopsy or fine‑needle aspiration (FNA) of suspicious neck nodes is performed. Pathology confirms the histologic type and evaluates EBV‑encoded RNA (EBER) by in‑situ hybridization—a hallmark of non‑keratinizing NPC.

Laboratory tests

• Serum EBV DNA levels – higher titers correlate with tumor burden and are used for monitoring.
• Complete blood count, liver and kidney function tests – baseline before treatment.
• HPV testing – rarely positive in NPC but performed when indicated.

Staging

NPC is staged using the AJCC (American Joint Committee on Cancer) 8th edition TNM system, incorporating tumor size (T), nodal involvement (N), and presence of distant metastasis (M). Accurate staging guides treatment planning.

Treatment Options

Curative intent

Because NPC is highly radiosensitive, the mainstay of treatment is radiotherapy, often combined with chemotherapy.

• Intensity‑Modulated Radiotherapy (IMRT): Delivers high‑precision radiation to the tumor while sparing surrounding structures (e.g., brainstem, optic nerves).
• Concurrent chemoradiotherapy (CCRT): Platinum‑based agents (cisplatin) given during radiotherapy improve survival for stage III‑IV disease.
• Neoadjuvant (induction) chemotherapy: Administered before radiotherapy for large tumors or high EBV DNA levels.
• Adjuvant chemotherapy: Post‑radiotherapy chemo may be used in selected high‑risk patients.

Surgery

Primary surgery is rarely curative due to the deep location of the nasopharynx. However, minimally invasive endoscopic nasopharyngectomy may be considered for recurrent or residual disease after radiation.

Targeted & immunotherapy

• EGFR inhibitors (e.g., cetuximab): Investigational in combination with radiotherapy.
• PD‑1/PD‑L1 checkpoint inhibitors (e.g., pembrolizumab, nivolumab): FDA‑approved for recurrent/metastatic NPC after chemotherapy failure.

Supportive & home‑based care

• Nutrition support: High‑protein, high‑calorie diet; supplements if swallowing is difficult.
• Oral hygiene: Soft‑bristle toothbrush, salt‑water rinses to reduce mucositis.
• Pain management: Acetaminophen or low‑dose opioids as prescribed.
• Dry mouth (xerostomia) care: Frequent sips of water, sugar‑free lozenges, saliva substitutes.
• Psychosocial support: Counseling, support groups, and survivorship programs.

Prevention Tips

Because some risk factors are non‑modifiable (e.g., genetics, EBV exposure), prevention focuses on lifestyle and environmental modifications:

• Limit intake of preserved/salted foods: Reduce nitrosamine exposure by choosing fresh fish, poultry, and vegetables.
• Quit smoking and limit alcohol: Smoking cessation programs and moderation of alcohol lower overall head‑and‑neck cancer risk.
• Vaccinate against EBV (future prospect): Clinical trials are underway; eligible patients should consider enrollment.
• Maintain good oral hygiene: Regular dental check‑ups decrease chronic inflammation.
• Use protective equipment: Masks or respirators in occupations with wood dust, formaldehyde, or chemical fumes.
• Regular medical check‑ups for high‑risk groups: Annual ENT examinations and, if indicated, EBV DNA screening in endemic areas.
• Balanced diet rich in antioxidants: Fruits, leafy greens, and vitamin‑D‑rich foods may offer protective benefits.

Emergency Warning Signs

Key Takeaways

Nasopharyngeal cancer is a rare but aggressive malignancy that often presents with subtle ENT symptoms. Early recognition—especially of persistent unilateral nasal obstruction, unexplained neck nodes, and ear-related problems—can lead to timely diagnosis and curative treatment. While the disease is primarily managed with advanced radiotherapy and chemotherapy, lifestyle modifications and vigilance in high‑risk populations play an important role in prevention and early detection.

References

1. Mayo Clinic. Nasopharyngeal cancer. https://www.mayoclinic.org. Accessed May 2026.
2. National Cancer Institute. Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version. https://www.cancer.gov. Updated 2024.
3. World Health Organization. International Agency for Research on Cancer. Nasopharynx cancer fact sheet. https://www.iarc.who.int. 2023.
4. Cleveland Clinic. Nasopharyngeal cancer: Symptoms, diagnosis, treatment. https://my.clevelandclinic.org. 2025.
5. Zhang L, et al. Epstein–Barr virus DNA as a biomarker for nasopharyngeal carcinoma. J Clin Oncol. 2022;40(12):1465‑1474.
6. Lin JC, et al. Radiotherapy for nasopharyngeal carcinoma: IMRT versus conventional techniques. Radiother Oncol. 2021;151:12‑20.
7. American Society of Clinical Oncology. NCCN Guidelines®: Head and Neck Cancers, Version 3.2024.

```